New data, in addition to analyses by scientists at the FDA, may take some of the shine off Merck’s experimental Covid-19 pill, molnupiravir. On Friday, the drug maker released full results from its study of the pill, molnupiravir, showing it reduced the risk of hospitalization by 30%, down from a decrease of 50% seen in an earlier analysis. In the 1,433-patient study, fewer patients died when they received the treatment.